| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Flurofamide targets bacterial urease, an enzyme that catalyzes the hydrolysis of urea into ammonia and carbon dioxide. By inhibiting urease, the compound reduces ammonia production, which is important for the survival and virulence of urease-producing bacteria such as H. pylori and U. urealyticum. The compound also partially inhibits the chemotactic activity of H. pylori.
|
|---|---|
| ln Vitro |
Flurofamide demonstrates potent in vitro inhibition of bacterial urease. It inhibits the growth of Ureaplasma urealyticum. The compound's activity is typically assessed in urease activity assays measuring the production of ammonia from urea in the presence of the compound.
|
| ln Vivo |
In vivo activity of flurofamide has been suggested by its potential clinical utility in the treatment of infection-induced urinary stones. By inhibiting urease, the compound may reduce the alkalinization of urine and the formation of struvite stones caused by urease-producing bacteria. Further in vivo studies are needed to evaluate its efficacy and safety.
|
| Enzyme Assay |
In vitro enzyme assays for flurofamide involve measuring its inhibition of urease activity. The assay typically uses bacterial urease (e.g., from H. pylori or Jack bean) and measures the production of ammonia from urea using colorimetric or pH-based methods. IC50 values can be determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for flurofamide involve culturing urease-producing bacteria (e.g., H. pylori, U. urealyticum) in the presence of varying concentrations of the compound. Antibacterial activity is assessed by measuring inhibition of growth using optical density measurements or colony counting. Urease inhibition can be confirmed by measuring ammonia production in culture supernatants.
|
| Animal Protocol |
In vivo animal experiments for flurofamide are not extensively documented. If used in animal models, typical protocols would involve administering the compound to animals infected with urease-producing bacteria and evaluating efficacy by measuring bacterial load, urinary pH, or stone formation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for flurofamide are limited. The compound has a molecular weight of 217.14 and a molecular formula of C7H9FN3O2P. Its absorption, distribution, metabolism, and excretion properties have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for flurofamide are limited. As a research compound, comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Millner OE Jr, et al. Flurofamide: a potent inhibitor of bacterial urease with potential clinical utility in the treatment of infection induced urinary stones. J Urol. 1982 Feb;127(2):346-50.
|
| Additional Infomation |
N-Diaminophosphoryl-4-fluorobenzamide is an organohalide compound and a carbonyl compound.
Flurofamide (CAS#: 70788-28-2) has the molecular formula C7H9FN3O2P and a molecular weight of 217.14. It is a phosphorodiamidate-based competitive inhibitor of bacterial urease. The compound has potential in the treatment of infection-induced urinary stones. It is for research use only. |
| Molecular Formula |
C7H9FN3O2P
|
|---|---|
| Molecular Weight |
217.14
|
| Exact Mass |
217.042
|
| CAS # |
70788-28-2
|
| PubChem CID |
51173
|
| Appearance |
White to off-white solid powder
|
| Density |
1.457g/cm3
|
| Index of Refraction |
1.574
|
| LogP |
2.372
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
260
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
c1cc(ccc1C(=O)NP(=O)(N)N)F
|
| InChi Key |
QWZFVMCWPLMLTL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9FN3O2P/c8-6-3-1-5(2-4-6)7(12)11-14(9,10)13/h1-4H,(H5,9,10,11,12,13)
|
| Chemical Name |
N-diaminophosphoryl-4-fluorobenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 14.29 mg/mL (65.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.43 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.43 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.43 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6053 mL | 23.0266 mL | 46.0532 mL | |
| 5 mM | 0.9211 mL | 4.6053 mL | 9.2106 mL | |
| 10 mM | 0.4605 mL | 2.3027 mL | 4.6053 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
